# A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects With Chronic Hepatitis B Virus Infection

> **NCT05414981** · PHASE1 · COMPLETED · sponsor: **Assembly Biosciences** · enrollment: 31 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** ABI-H3733
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05414981
- **Lead sponsor:** Assembly Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-07
- **Primary completion:** 2023-04-24
- **Final completion:** 2023-04-24
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2023-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05414981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05414981, "A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects With Chronic Hepatitis B Virus Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05414981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*